DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report information for the calendar year 2015 and anticipated income for 2016. For audit purposes, please keep conflict of interest/financial records for three years after the conclusion of the award.

How to Use This Form:

- 1) Save the document on your drive.
- 2) Enter the Year (e.g. 2015/2016), your Name, Title and Address in the appropriate fields.
- 3) Make sure you save your version on your drive.
- 4) Then Click on "File", click "Protect Document", in the drop-down menu click "Restrict Editing". In the column to the right at the bottom click "unprotect".
- 5) Click on the appropriate checkboxes.
- 6) Save your updated version on your drive
- 7) Send an email to DCRI Corporate Communications (<u>DCRI-Comms@dm.duke.edu</u>) with your COI attached for posting on our DCRI website.

Editing the Document (Necessary only when you have to add companies not on the form):

- 1) Scroll down to the last page to the blank rows and enter the company name(s) on the company field(s).
- 2) Enter new information.
- 3) Click on the appropriate checkboxes on your new listing and save.
- 4) Make sure you save your version on your drive.

Column Explanations:

- (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds.
- (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (5) I receive personal income outside of my University salary for consulting or other non-CME services from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (6) I personally receive royalties in excess of \$5,000 per year from this company.
- (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > \$5,000 or > 1%.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Year(s):	015
Name:	Melissa Daubert MD
Title:	ssistant Professor of Medicine, Cardiology
Address:	uke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Company:	(1) A Research Grant or Contract from this Company Partially	(2) A Research Grant or Contract from this Company Supports My Research Projects	(3) Educational Activities or Lectures for this Company Generates Revenue for Duke			(4) Consulting or Other Services (Including CME) for this Company Generates Personal Income			(5) Consulting or Other non-CME Services for this Company Generates Personal Income			(6) I Receive Significant Personal Royalties from this	(7) I Have Equity in this Company	
	Supports My University Salary		<\$5K	\$5K- \$25K	>\$25K	<\$5K	\$5K- \$25K	>\$25K	<\$5K	\$5K- \$25K	>\$25K	Company	<\$5 K	>\$5K/1%
Abbott Laboratories														
Abiomed														
Acerta Pharma														
Achillion Pharmaceuticals														
Acorda Therapeutics, Inc														
Aires Pharmaceuticals														
Akili Interactive Labs														
Alcobra														
Amgen, Inc.														
Amylin Pharmaceuticals, Inc.														
ARCA Biopharma														
Ardea Biosciences, Inc.														
Armetheon Inc														

AstraZeneca							
Atentiv Inc							
Baseline Study LLC							
Baxalta							
Bayer Corporation US (Bayer AG/Bayer in Japan – subsidiaries)							
Beckman Research Institiute							
Bellerophon Therapeutics							
Biogen							
Biogen Idec In							
Biomarin							
Biosensors International Group Ltd							
BioStealth Inc							
Boehringer Ingelheim							
Boston Scientific Corporation							
Bristol Myers Squibb							
Burroughs Welcome Fund							
Cardio3 Bioscience							
CardioDx, Inc.							
Cardiovascular Systems, Inc.							
Cempra Pharmaceuticals, Inc.							
Cerenova, LLC							
CPC Clinical Research							

CSL Group								
CSL Limited								
Cubist Pharmaceuticals								
Daiichi Sankyo Co. Limited								
Deloitte Consulting LLP								
Dr. Reddy's Laboratories LTD								
Duke Clinical Research Institute								
Duke Neurology Imaging Lab								
Durata Therapeutics								
Edwards Lifesciences	Χ□	Χ□						
Elesvier								
Eli Lilly & Company								
Evalve, Inc								
Exelixis, Inc.								
F Hoffmann-La Roche Ltd								
Ferring Pharmaceuticals								
Genentech								
General Electric Company								
General Electric Healthcare								
Genetic Alliance								
Genzyme Corporation								
Gilead Sciences, Inc.								
Glaxo SmithKline (GSK)								

Grifols							
Harvard Pilgrim Health Care							
HeartFlow							
Hologic, Inc.							
Humacyte, Inc							
Immuron Ltd							
Janssen Pharmaceutica Products, L.P.							
Janssen Research and Development, LLC							
Janssen Scientific Affairs, LLB							
Johnson & Johnson							
Johnson & Johnson Pharmaceutical Research & Development							
LadeRX							
Luitpold Pharmaceuticals, Inc.							
MAQUET Cardiovascular LLC (formerly Boston Scientific Cardiac & Vascular)							
Marinus Pharmaceuticals Inc							
Medical Education Solutions Group							
MedImmune Inc							
Medscape, LLC							
Medtronic PLC							

Medtronic Vascular, Inc. (formerly Medtronic AVE)								
Merck & Co., Inc								
Merck Sharp & Dohme I.A. Corporation								
MyoKardia Inc								
Novartis Consumer Health Inc								
Novartis Pharmaceutical Company								
Novavax Inc								
Ophthotech Corporation								
OrbusNeich								
Otsuka America Pharmaceutical								
Oxygen Biotherapeutics (Formerly SBI)								
Pfizer								
Popluation Health Research Institute								
Portola Pharmaceutical								
Procyrion Inc								
Reflexion Health								
Regeneron Pharmaceuticals, Inc.								
Research Triangle Institute								
ResMed	Χ□	Χ□						
RespireRX Pharmaceuticals								

Roche Diagnostics	Χ□	Χ□						
Roche Diagnostics Corp								
Roche Group								
Sanofi-Aventis								
Shionogi Inc								
Society of Thoracic Surgeons								
Stealth Peptides	Χ□	Χ□		X				
Summit								
Swedish Orphan Biovitrum AB								
Tacere Therapeutics								
Taiwanj Pharmaceuticals Company Ltg								
The Medicines Company								
Theravance Biopharma								
Thrombosis Research Institute								
Tokalas Inc								
University of Michigan								
Verily Life Sciences								
Zimmer Biomet Holdings Inc								

Column Explanations:

- (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds.
- (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (5) I receive personal income outside of my University salary for consulting or other non-CME services from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (6) I personally receive royalties in excess of \$5,000 per year from this company.
- (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > \$5,000 or > 1%.